{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:03:32Z","timestamp":1768079012342,"version":"3.49.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.jsps.2012.12.003","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T06:34:02Z","timestamp":1355985242000},"page":"423-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Methotrexate for the treatment of generalized vitiligo"],"prefix":"10.1007","volume":"21","author":[{"given":"Khalid","family":"AlGhamdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huma","family":"Khurrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"8","key":"10.1016\/j.jsps.2012.12.003_b0015","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-4632.2006.02744.x","article-title":"Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo","volume":"45","author":"Birol","year":"2006","journal-title":"Int. J. Dermatol."},{"issue":"5","key":"10.1016\/j.jsps.2012.12.003_b0005","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1600-0749.2006.00333.x","article-title":"A review and a new hypothesis for nonimmunological pathogenetic mechanisms in vitiligo","volume":"19","author":"Dell\u2019anna","year":"2006","journal-title":"Pigm. Cell Res."},{"issue":"20","key":"10.1016\/j.jsps.2012.12.003_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399401003362","article-title":"Immunological pathomechanisms in vitiligo","volume":"3","author":"Kemp","year":"2001","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.jsps.2012.12.003_b0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archderm.1969.01610250076018","article-title":"Treatment of pemphigus vulgaris with methotrexate","volume":"100","author":"Lever","year":"1969","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jsps.2012.12.003_b0025","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.4049\/jimmunol.167.5.2911","article-title":"Methotrexate suppresses NF-kappaB activation through inhibition of Ikappa Balpha phosphorylation and degradation","volume":"167","author":"Majumdar","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jsps.2012.12.003_b0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/ard.59.4.311","article-title":"Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4","volume":"59","author":"Rudwaleit","year":"2000","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jsps.2012.12.003_b0030","first-page":"309","article-title":"Unstable vitiligo responding to methotrexate","volume":"64","author":"Sandra","year":"1998","journal-title":"Indian J. Dermatol. Venereol Leprol."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016412001284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016412001284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:27:21Z","timestamp":1736184441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016412001284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1319016412001284"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2012.12.003","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate for the treatment of generalized vitiligo","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2012.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}